EMA News
🇪🇺 EMA Page 5EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Get critical EMA regulatory updates for drug approvals, clinical trials, and market access in Europe & UK. Stay ahead of pharma compliance.
Showing 49–60 of 69 articles
European Biomarker-Driven Trials: EMA Regulatory Framework & Success Rates
HTA Outcomes Oncology Drugs: EU Regulation Impact on Germany, France, Italy
EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Development & Market Exclusivity
EMA CHMP Recommends Five New Medicines Including Tolebrutinib (Cenrifki) for Approval in April 2026
Phase 1 Trial Evolution: EMA’s New Safety Monitoring Requirements Explained
Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO
EMA Cell Therapy Framework: Impact on CAR-T Availability in Europe
NICE Technology Appraisals & G-BA Assessments for EMA-Approved Oncology Drugs 2026
CAR-T Therapies Cost-Effectiveness: EU HTA Bodies' Divergent Assessments
Real-World Evidence EU Drug Development: EMA's Hybrid Trial Framework
EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026
EMA AI System for Faster Drug Safety Signal Detection